IDH1

IDH1

IDH1 Overview

Molecule Name
Isocitrate dehydrogenase [NADP] cytoplasmic
Synonyms
IDH1,PICD,IDP
Drug Development Progress
Drugs in Clinical Trials11
Approved Drugs3
Highest Development StageApproved
Target Synonym
IDH,EC 1.1.1.42,PICD,IDCD,Isocitrate Dehydrogenase (NADP(+)) 1,Isocitrate Dehydrogenase 1 (NADP+), Soluble,HEL-S-26,IDH1,Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic,HEL-216,NADP(+)-Specific ICDH,Cytosolic NADP-Isocitrate Dehydrogenase,IDP,NADP-Dependent Isocitrate Dehydrogenase, Cytosolic,Oxalosuccinate Decarboxylase,Epididymis Secretory Protein Li 26,Isocitrate Dehydrogenase 1 (NADP+),NADP-Dependent Isocitrate Dehydrogenase, Peroxisomal,IDPC,EC:1.1.1.42,Epididymis Luminal Protein 216,Epididymis Secretory Sperm Binding Protein,Isocitrate Dehydrogenase [NADP] Cytoplasmic
Background
The IDH enzymes catalyze the oxidative decarboxylation of isocitrate to alpha-ketoglutarate (α-KG), producing nicotinamide adenine dinucleotide phosphate (NADPH) in the process via the citric acid cycle. Eukaryotic cells express two distinct classes of IDHs that utilize either NAD or NADP as their cofactors and serve diverse biological functions. NAD-dependent IDH is localized to the mitochondrial matrix and is well known for its central role for energy production in the Krebs cycle. NADP-dependent IDHs are primarily located either in mitochondria or cytoplasm . Each NADP-dependent isozyme is a homodimer. Mutations of Arg132 of human IDH1 result in a reduced ability of the enzyme to convert isocitrate to alpha ‑ketoglutarate, but the enzyme acquires the ability to generate 2-hydroxyglutarate (2HG) from alpha‑ketoglutarate,2-HG is elevated in several tumor types, including a subset of AMLs.

IDH1 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
SafusidenibDS-1001b; DS-1001; AB-218Phase 3 ClinicalDaiichi Sankyo Co Ltd
Astrocytoma; Biliary Tract Neoplasms; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours
Details
RanosidenibHMPL-306Phase 3 Clinical
Glioma; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Solid tumours
Details
TQB-3454TQB-3454; CT-2755Phase 3 ClinicalBeijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Bile Duct Neoplasms; Biliary Tract Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Solid tumours
Details
MT-001MT-001; MT001Phase 2 ClinicalZhejiang Meton Pharmaceutical Co Ltd
Neoplasms; Solid tumours
Details
BAY-1436032BAY-1436032Phase 1 ClinicalBayer AG
Leukemia, Myeloid, Acute; Solid tumours
Details
IDH-305IDH-305Phase 1 ClinicalNovartis Pharma Ag
Glioma; Leukemia, Myeloid, Acute; Neoplasms
Details
IDH1/2 inhibitor (Eli Lilly)Phase 1 ClinicalEli Lilly And Company
Neoplasms
Details
BPI-221351BPI-221351Phase 1 ClinicalBetta Pharmaceuticals Co Ltd
Glioma; Solid tumours
Details
KY-100001KY-100001Phase 1 ClinicalKpc Pharmaceuticals Inc
Solid tumours
Details
HH-2301HH-2301; HH2301Phase 1 ClinicalShangHai HaiHe Biopharma Co Ltd
Biliary Tract Neoplasms; Chondrosarcoma; Glioma; Solid tumours
Details
LY-3410738LY-3410738Phase 1 ClinicalEli Lilly And Company
Cholangiocarcinoma; Chondrosarcoma; Glioma; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Solid tumours
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
IvosidenibCS-3010; S-95031; CS 3010; AG-120ApprovedAgios Pharmaceuticals Inc拓舒沃, Tidhesco, Tibsovo, TIBSOVO, Tuoshuvo, TosuvoUnited StatesLeukemia, Myeloid, AcuteServier Pharmaceuticals Llc2018-07-20
Bile Duct Neoplasms; Cholangiocarcinoma; Chondrosarcoma; Ependymoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Hepatoblastoma; Histiocytosis, Langerhans-Cell; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Medulloblastoma; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasms; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neuroectodermal Tumors, Primitive, Peripheral; Osteosarcoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Sarcoma, Myeloid; Solid tumours; Wilms Tumor
Details
VorasidenibAG-881; AGI-23088; S-95032; S95032ApprovedAgios Pharmaceuticals IncVORANIGOUnited StatesAstrocytoma; Oligodendroglioma; GliomaServier Pharmaceuticals Llc, Laboratoires Servier2024-08-06
Astrocytoma; Ganglioglioma; Glioblastoma; Glioma; Hematologic Neoplasms; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Liver Diseases; Liver Dysfunction; Myelodysplastic Syndromes; Oligodendroglioma
Details
OlutasidenibFT-2102ApprovedForma Therapeutics Holdings IncRezlidhiaUnited StatesLeukemia, Myeloid, AcuteRigel Pharmaceuticals Inc2022-12-01
Chondrosarcoma; Diarrhea; Irritable Bowel Syndrome; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Leukemia, Promyelocytic, Acute; Myelodysplastic Syndromes
Details